A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
K. Gelmon, H. Hirte, B. Fisher, W. Walsh, M. Ptaszynski, M. Hamilton, N. Onetto, E. EisenhauerVolume:
22
Language:
english
Pages:
13
DOI:
10.1023/b:drug.0000026252.86842.e2
Date:
August, 2004
File:
PDF, 283 KB
english, 2004